Strong Demand for Specialty Medicines Pushes GSK Profits Higher

GlaxoSmithKline (GSK) has recorded a significant increase in annual profit, driven by strong demand for its specialty medicines. The company’s net earnings for 2025 rose to £5.7 billion, up notably from the previous year, thanks to treatments in areas like HIV, respiratory, and cancer care.

Total revenue reached £32.7 billion, showing steady growth compared with 2024. Sales of specialty medicines climbed around 17 per cent to £13.5 billion, highlighting their growing importance to GSK’s overall performance. Vaccines also contributed to revenue growth, while general medicines experienced a slight decline.

Luke Miels, who became chief executive earlier this year, described the results as a “strong performance” and reaffirmed the company’s long‑term growth targets, even as overall sales growth is expected to slow in 2026 due to challenging market conditions.

The positive earnings report boosted investor confidence, with GSK shares responding favorably as the company’s focus on high‑growth therapeutic areas continues to pay off.

GSK’s results underscore the increasing role of specialty medicines in its strategy and signal robust performance in key global markets.